cyclohexyl), alkenyl (such as vinyl, 1- or 2-propenyl, and 1-butenyl), alkynyl (such as ethynyl, 1- or 2-propynyl, 1-, 2-, or 3-butynyl, and 1-methyl-2-propynyl), alkoxy (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, *tert*-butoxy, pentyloxy, isopentyloxy, and hexyloxy), acyl (such as formyl, acetyl, propionyl, ~~butynyl~~butyryl, ~~isobutynyl~~isobutyryl, and benzoyl), acyloxy (such as formyloxy, acetyloxy, propionyloxy, ~~butynyloxy~~butyryloxy, ~~isobutynyloxy~~isobutyryloxy, and benzoyloxy), alkoxycarbonyl (such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, *tert*-butoxycarbonyl, pentyloxycarbonyl, isopentyloxycarbonyl, and hexyloxycarbonyl), saturated heterocyclic groups (such as azetidino, pyrrolidino, imidazolidino, oxazolidino, thiazolidino, piperazino, piperidino, morpholino, and thiomorpholino), unsaturated heterocyclic groups (such as furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, quinolyl, isoquinolyl, benzo[b]thienyl, and benzimidazolyl), aromatic hydrocarbon groups (such as phenyl, naphthyl, tolyl, xylyl, anthracenyl, phenanthrenyl, and biphenylyl), alkylamino (such as methylamino, ethylamino, *n*-propylamino, isopropylamino, *n*-butylamino, isobutylamino, *sec*-butylamino, *tert*-butylamino, *n*-pentylamino, and *n*-hexylamino), acylamino (such as formylamino, acetylamino, propionylamino, ~~butynylamino~~butyrylamino, ~~isobutynylamino~~isobutyrylamino, and benzoylamino), aralkyloxy (such as benzyloxy, phenethyloxy, phenylpropyloxy, and naphthylmethyloxy), and the like. Hydroxyl is preferable. When such substituents are present, the number thereof is typically one to three.

[0023]

In the present specification, the term "deuterated" indicates that one to all of the hydrogen atoms of R are replaced by deuterium, and preferably indicates that two to seven of the hydrogen atoms of R are replaced by deuterium.

[0024]

CLAIMS

[Claim 1]

An acetic acid ester compound represented by the following formula or a salt thereof,



wherein R represents optionally substituted deuterated lower alkyl.

[Claim 2]

The acetic acid ester compound according to claim 1 or a salt thereof, wherein R represents deuterated straight C_{1-6} alkyl.

[Claim 3]

The acetic acid ester compound according to claim 1 or 2 or a salt thereof, wherein R represents *n*-propyl in which 2 to 7 of the hydrogen atoms are replaced by deuterium.

[Claim 4]

The acetic acid ester compound according to any of claims 1 to 3 or a salt thereof, wherein R represents propyl-2,2,3,3,3-d5, propyl-1,1,2,2,3,3,3-d7, propyl-1,1-d2, propyl-2,2-d2, propyl-3,3,3-d3, or propyl-1,1,2,2-d4.

[Claim 5]

An acetic acid ester compound of any of the following (a) to (f), or a salt thereof:

(a) 4-piperidinyl 2,2-diphenyl-2-(propoxy-2,2,3,3,3-d5)acetate,

(b) 4-piperidinyl 2,2-diphenyl-2-(propoxy-

1,1,2,2,3,3,3-d7)acetate,

(c) 4-piperidinyl 2,2-diphenyl-2-(propoxy-1,1-d2)acetate,

(d) 4-piperidinyl 2,2-diphenyl-2-(propoxy-2,2-d2)acetate,

(e) 4-piperidinyl 2,2-diphenyl-2-(propoxy-3,3,3-d3)acetate, and

(f) 4-piperidinyl 2,2-diphenyl-2-(propoxy-1,1,2,2-d4)acetate.

[Claim 6]

A pharmaceutical composition comprising an effective amount of the acetic acid ester compound according to any of claims 1 to 5 or a salt thereof, and a pharmaceutical carrier.

[Claim 7]

(Amended) A prophylactic and/or therapeutic agent for a disease that is expected to be ameliorated by an increase in intraurethral pressure, the agent comprising an effective amount of the acetic acid ester compound according to any of claims 1 to 5 or a salt thereof, and a pharmaceutical carrier.

[Claim 8]

A prophylactic and/or therapeutic agent for stress urinary incontinence, the agent comprising an effective amount of the acetic acid ester compound according to any of claims 1 to 5 or a salt thereof, and a pharmaceutical carrier.

~~[Claim 9]~~

~~A method for preventing and/or treating a disease that is expected to be ameliorated by an increase in intraurethral pressure, the method comprising administering an effective amount of the acetic acid ester compound according to any of claims 1 to 5 or a salt thereof.~~

~~[Claim 10]~~

~~The method according to claim 9, wherein the disease that is expected to be ameliorated by an increase in intraurethral pressure is stress urinary incontinence.~~

[Claim ~~11~~9]

The acetic acid ester compound according to any of claims 1 to 5 or a salt thereof for preventing and/or treating a disease that is expected to be ameliorated by an increase in intraurethral pressure.

~~[Claim 12]~~

~~Use of the acetic acid ester compound according to any of claims 1 to 5 or a salt thereof for preventing and/or treating a disease that is expected to be ameliorated by an increase in intraurethral pressure.~~

[Claim ~~13~~10]

Use of the acetic acid ester compound according to any of claims 1 to 5 or a salt thereof for the production of a prophylactic and/or therapeutic agent for a disease that is expected to be ameliorated by an increase in intraurethral pressure.